Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Aducanumab (BIIB037)
Drug: Placebo

First Posted Date: 2015-06-23

Last Posted Date: 2021-09-02

Lead Sponsor: Biogen

Target Recruit Count: 1653

Registration Number: NCT02477800

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇮🇹
Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Ancona, Italy
🇵🇹
Centro Hospitalar e Universitário de Coimbra E.P.E, Coimbra, Portugal

and more 152 locations

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis

Phase 4

Withdrawn

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: dimethyl fumarate
Other: Placebo

First Posted Date: 2015-06-16

Last Posted Date: 2015-12-28

Lead Sponsor: Biogen

Registration Number: NCT02472938

Tecfidera and the Gut Microbiota

Phase 4

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: injectable MS DMT
Drug: dimethyl fumarate

First Posted Date: 2015-06-15

Last Posted Date: 2021-09-05

Lead Sponsor: Biogen

Target Recruit Count: 36

Registration Number: NCT02471560

Locations: 🇳🇴
Research site, Stavanger, Norway
🇳🇴
Research Site, Lillehammer, Norway

A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).

Phase 2

Terminated

Conditions: Spinal Muscular Atrophy

Interventions: Drug: Nusinersen
Procedure: Sham Procedure

First Posted Date: 2015-06-04

Last Posted Date: 2021-02-17

Lead Sponsor: Biogen

Target Recruit Count: 21

Registration Number: NCT02462759

Locations: 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Connecticut Childrens Medical, Hartford, Connecticut, United States
🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 4 locations

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Phase 1

Completed

Conditions: Progressive Supranuclear Palsy

Interventions: Drug: BIIB092
Drug: Placebo

First Posted Date: 2015-06-02

Last Posted Date: 2018-09-04

Lead Sponsor: Biogen

Target Recruit Count: 48

Registration Number: NCT02460094

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Francisco, Medical Center at Parnassus, San Francisco, California, United States

and more 10 locations

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Phase 1

Completed

Conditions: Healthy
Parkinson's Disease

Interventions: Drug: BIIB054
Drug: Placebo

First Posted Date: 2015-06-02

Last Posted Date: 2019-08-08

Lead Sponsor: Biogen

Target Recruit Count: 66

Registration Number: NCT02459886

Locations: 🇺🇸
Research Site, Spokane, Washington, United States

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIB118

First Posted Date: 2015-05-14

Last Posted Date: 2021-02-17

Lead Sponsor: Biogen

Target Recruit Count: 32

Registration Number: NCT02443740

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Aducanumab
Drug: Placebo

First Posted Date: 2015-05-05

Last Posted Date: 2020-08-21

Lead Sponsor: Biogen

Target Recruit Count: 21

Registration Number: NCT02434718

Locations: 🇯🇵
Research Site, Kyoto, Japan

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

Phase 3

Terminated

Conditions: Multiple Sclerosis, Secondary Progressive

Interventions: Drug: dimethyl fumarate
Other: Placebo

First Posted Date: 2015-04-30

Last Posted Date: 2017-04-26

Lead Sponsor: Biogen

Target Recruit Count: 58

Registration Number: NCT02430532

Locations: 🇸🇰
Research Site, Banska Bystrica, Slovakia

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase 3

Withdrawn

Conditions: Relapsing-Remitting Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis

Interventions: Drug: dimethyl fumarate
Drug: Placebo

First Posted Date: 2015-04-28

Last Posted Date: 2016-04-13

Lead Sponsor: Biogen

Registration Number: NCT02428218

Home Terms & Conditions Privacy Policy